期刊文献+

靶向共价键药物的研究进展 被引量:2

Research Progress of Targeted Covalent Drugs
原文传递
导出
摘要 药物与靶标的结合是启动药理作用的本源,共价键药物是以共享电子的方式来实现与靶标的结合,其中大多为抗感染、抗肿瘤以及心脑血管、神经系统和代谢类药物。简介共价键药物与非共价键药物的区别以及既往的重磅级共价键药物与靶标的结合特点,分类综述靶向共价键药物的理性设计及与靶标的结合反应。 Pharmacological effects origilmte from tile interactions of drugs with targets. The covalent bindings of drugs to targets are achievedby sharing electron pairs, which have been tbund mostly in the interactions of the drugs for infction, tumor and the central nervous system, cardio-cerebrovascular and metabolic diseases with their targets. The distinction between covalent drug and non-covalent drug and tile binding tbatures of the launched heavyweight covalent drugs to their targets were introduced. The rational design of covalent drugs and their binding reactions withtheir targets were reviewed classifiedly.
作者 郭宗儒
出处 《药学进展》 CAS 2013年第11期555-564,共10页 Progress in Pharmaceutical Sciences
关键词 共价键药物 药物理性设计 药物-靶标结合反应 covalent drug rational drug design drug-target binding reaction
  • 相关文献

参考文献21

  • 1Potashman M H, Duggan ME. Covalent modifiers: an orthogonal approach to drug design [J].J MedChem, 2009, 52(5): 1231-1246.
  • 2Singh J, Petter R C, Baillie T A, eta/. The resurgence of covalent drugs[J]. NatRevorugolscov, 2012, 10(4): 307-317.
  • 3Kalgutkar A S, Dalvie D K. Drug discovery for a new generation of covalent drugs[J]. Expert Opin Drug Dicov, 2(112, 7 (7):561-581.
  • 4Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs[J]. Nat New Biol, 1971, 231(25): 232-235.
  • 5Pereillo J M, Maftouh M, Andrieu A, etal. Structure and stereochenfistry of the active metabolite of clopidogrel[J]. Dnlg Metab Dispos, 2002, 30(11): 1288-1295.
  • 6Cattaneo M. ADP receptors: inhibitory strategies for antiplatelet therapy[J]. Dnzg News Perspect, 2006, 19(5): 253-259.
  • 7Elander B, Blandstrom A, Larsson H. Evidence for acid-induced transformation of omeprazole into an active inhibitor of H+/ K+-ATPase within the parietal cell[J]. Biochim Biophys Acta 1984,778(3):546-558.
  • 8Schroder J, Klinger A, Oellien F, et al. Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach[J].J Ailed Chem, 2013, 56(4): 1478-1490.
  • 9Bernier S G, Westlin W F, Hannig G. Fumagillin class inhibitors of methionine aninopeptidase-2[J]. Drugs Fur, 2005, 3(}(5): 497-508.
  • 10Hadvary P, Sidler W, Meister W, et al. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative site serine of pancreatic lipase[J].J Bool Chem, 1991, 266(4): 2021-2027.

同被引文献56

  • 1XIA Jing,XIA Li,WANG Wei-yi,SHA Yi-wei,WANG Ke,JI Shen.A Rapid and Effective HPLC Method for Identification of Bovis Calculus in Chinese Patent Medicines[J].Chinese Herbal Medicines,2013,5(3):224-233. 被引量:3
  • 2罗群力,李静雅,叶其壮,南发俊.甲硫氨酰氨肽酶的研究进展[J].中国药学杂志,2004,39(11):804-808. 被引量:3
  • 3王敏,张月琴.以组织蛋白酶K为靶点的新药筛选[J].中国抗生素杂志,2005,30(6):373-379. 被引量:3
  • 4王长云,邵长伦.海洋药物学[M].北京:科学出版社,2011:204-344.
  • 5Singh J,Petter R C,Baillie T A,et al. The resurgence of co valent drugs[J].Nat Rev Drug Diseov, 2012, 10(4): 307- 317.
  • 6Hadvary P,Sidler W,et al. The Lipase Inhibitor Tetrahydro- lipstatin Binds Covalently to the Putative Active Site Serine of Pancreatic Lipase [J]. Biol Chem, 1991,266 ( 4 ) : 2021- 2027.
  • 7Zhi J, Melia A T, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers[J]. J Clin Pharmacol, 1995,35 : 1103-1108.
  • 8Fako V E,Zhang J, Liu J. Mechanism of ()rlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase [J].ACS Catal, 2014,4 : 3444-3453.
  • 9Pernhle C W,Johnson L C,and Lowther W T. Crystal struc- ture of the thioesterase domain of human fatty acid synthase inhibited by Orlistat[J].Nat Struct Mol Biol,2007, 14:704- 709.
  • 10Peters J U. 11 Years of Cyanopyrrolidines as DPP-IV Inhibi- tors [J].Curt Top Med Chem,2007,7(6):579-595.

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部